Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18
2011

Using Coxsackieviruses to Treat Melanoma

Sample size: 21 publication Evidence: moderate

Author Information

Author(s): Au Gough G, Beagley Leone G, Haley Erin S, Barry Richard D, Shafren Darren R

Primary Institution: The University of Newcastle

Hypothesis

Can Coxsackieviruses A13, A15, and A18 effectively reduce malignant melanoma tumors?

Conclusion

Coxsackieviruses A13, A15, and A18 can effectively reduce tumor volumes in melanoma models.

Supporting Evidence

  • Coxsackieviruses A13, A15, and A18 showed significant tumor volume reduction in melanoma models.
  • No pre-existing neutralizing antibodies against CVA13, CVA15, or CVA18 were found in melanoma patients.
  • CVA18 was particularly effective, leading to complete tumor clearance in some cases.

Takeaway

Scientists are testing certain viruses to see if they can help fight skin cancer by making the cancer cells go away.

Methodology

The study involved in vitro and in vivo experiments using melanoma cell lines and mouse models to assess the oncolytic activity of the viruses.

Potential Biases

Potential bias due to the involvement of authors with financial interests in the research.

Limitations

The study's findings may not be generalizable due to the limited sample size and specific patient demographics.

Participant Demographics

15 late-stage melanoma patients and 6 healthy volunteers.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1743-422X-8-22

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication